Phospholipids as cardiovascular therapeutics.
A uniquely formulated soy phospholipid is being developed as a potential therapeutic for the treatment and prevention of heart disease. Three phase I and one phase I/II clinical trials have been completed with soy phosphatidylinositol (PI). The compound was shown to be safe in all trials and at doses over 5 g. Clinical studies have also shown early-stage efficacy to suggest that PI is able to raise plasma HDL-cholesterol and apolipoprotein A-I levels, and reduce triglyceride levels in humans. PI directly impacts plasma HDL levels through a MAPK stimulation of HDL production by the liver. Research has shown that the linoleic acid content of soy PI is critical to a peroxisome proliferator-activated receptor alpha dependent stimulation of HDL secretion. Soy-derived phospholipids uniquely affect cellular signaling and transcriptional processes. These lipids are safe and efficacious in humans and may therefore offer a novel therapeutic opportunity to treat cardiovascular disease.
Pandey
Nihar R
NR
Liponex Inc, Ottawa, Ontario K1Y 4W7, Canada.
Sparks
Daniel L
DL
D000818:Animals; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D006801:Humans; D007413:Intestinal Mucosa / Q000378:metabolism; D050356:Lipid Metabolism / Q000187:drug effects; D010743:Phospholipids / Q000378:metabolism / Q000627:therapeutic use*
D010743:Phospholipids